Physician profile
Seth E Gillespie
NPI 1457723538
$5,099.32
in general payments reported to CMS, 2019-2025
34 companies · $1,622 in 2025
The $1,622 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $243 · 2022: $831 · 2023: $1,353 · 2024: $1,051 · 2025: $1,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,025.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,025.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,251.00 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $709.36 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $534.40 | 2021-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $420.67 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $292.80 | 2022-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.50 | 2022-2025 | Jardiance |
| Abbott Laboratories | $198.15 | 2022-2025 | Freestyle Libre 3, Proclaim, Eterna |
| Saluda Medical Americas, INC. | $154.26 | 2025 | Evoke |
| Redhill Biopharma INC. | $136.07 | 2021-2024 | Talicia |
| Lilly USA, LLC | $131.18 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $94.86 | 2021-2023 | |
| Pfizer INC. | $94.01 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $93.19 | 2021-2024 | Gardasil 9, Capvaxive, Gardasil |
| Boston Scientific Corporation | $82.77 | 2022-2025 | Superion Indirect Decompression System, Wavewriter Alpha Prime 16 |
| Dexcom, INC. | $76.74 | 2024-2025 | Dexcom G6 Transmitter |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $71.81 | 2023 | |
| Lucid Diagnostics INC. | $65.48 | 2022-2024 | |
| Sanofi Pasteur INC. | $58.15 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $45.35 | 2025 | Recorlev |
| Glaxosmithkline, LLC. | $44.35 | 2022-2023 | Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $38.39 | 2022-2023 | Xarelto |
| Cranial Technologies, INC | $33.66 | 2022-2023 | Doc Band |
| Nevro Corp. | $33.46 | 2022 | |
| Shield Therapeutics INC | $32.68 | 2022-2024 | |
| Nalu Medical, INC. | $32.03 | 2023 | Nalu Neurostimulation System |
| Actelion Pharmaceuticals US, INC. | $29.15 | 2024 | Opsumit, Uptravi |
| Astellas Pharma US INC | $19.83 | 2023 | Myrbetriq |
| Qiagen, LLC | $19.49 | 2025 | |
| Gilead Sciences, INC. | $18.29 | 2025 | |
| Novartis Pharmaceuticals Corporation | $17.22 | 2022 | |
| Exact Sciences Corporation | $16.87 | 2023 | Cologuard Collection Kit |
| Corcept Therapeutics | $16.57 | 2025 | Korlym |
| Intra-Sana Laboratories | $16.03 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Medtronic, INC. | $14.55 | 2025 | Micra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Gillespie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.